Given recent retrospective study showing potential lack of benefit with bortezomib-based maintenance therapy (Bumma et al., PMID 37021929).
High-risk as defined by: deletion 17p/monosomy 17, t(14;16), t(4;14), t(14;20), or abnormality in 1q (gain or amplification)
Would you follow this guideline for maintenance ev...
This is a great answer encapsulating both definiti...